Comparison of ivermectin SR bolus, benzimidazole anthelmintics, and topical fenthion on productivity of stocker cattle from grazing through feedlot.

A study was conducted to determine the effect of different parasite control programs on weight gain and other measurements for stocker beef calves during the grazing season and subsequent feedlot phase of production. One hundred eighty recently weaned beef steers were purchased from a Mississippi sale barn and were allocated by restricted randomization on pretreatment weight to three treatments: (1) no anthelmintic treatment; treated only with a topical organophosphate (OP) during processing into the feedlot; (2) one benzimidazole (BZD) treatment at initiation of grazing, and a second given at the time of processing upon arrival at the feedlot, along with a topical OP; and (3) ivermectin sustained-release (SR) bolus administered at initiation of grazing, with no further treatment given at the feedlot. The cattle grazed separately by treatment for 125 days, with six replicated pastures per treatment; then were penned according to the same groupings after entry into the feedlot on day 127. Cattle were individually weighed at approximately 2-month intervals, and feed consumption was measured during the 167 days in the feedlot. Fecal nematode egg counts were individually monitored for all animals during both phases of the trial. Carcass weight, quality grade, yield grade, and the incidence of liver abscesses were recorded for each animal at slaughter. Cattle treated with the ivermectin SR bolus gained significantly (P < .05) more weight through the grazing period and from the start of grazing through the end of the feedlot phase than the controls or the cattle treated with BZD products. There were no significant differences in feed efficiency between any of the groups. Mean carcass weight for cattle treated with boluses was significantly (P < .05) greater than that of the controls and the group treated with BZD. Dressing percentage and quality grade were significantly (P < .05) higher for the BZD and bolus groups, and yield grade was slightly (but not significantly) better for each of these groups than for controls. Significantly (P < .05) fewer livers of cattle treated with boluses had abscesses at slaughter than did livers of controls or cattle treated with BZDs. During both phases of the trial, fecal egg counts were significantly (P < .05) lower for the group treated with boluses than for the untreated group or the group treated with BZD. These data indicate that treatment with boluses for parasite control at the beginning of the grazing period had beneficial effects on weight gain as compared to no anthelmintic treatment or treatment with a BZD at the start of grazing and again at the time of introduction into the feedlot. These bolus benefits were sustained through the feedlot phase of production and provided further improvements with significantly (P < .05) increased carcass weights. The bolus is a tool that can significantly increase the efficiency of production for cattle producers who retain ownership into the feedlot phase of production or feedlot operators who graze stockers before feedlot entry.

Safety of omeprazole paste in foals and mature horses.

Omeprazole has been shown to promote healing of spontaneously occurring gastric ulcers in horses when administered for 28 days at a dose of 4 mg/kg bwt/day and to prevent recurrence of ulcers in almost all horses when treatment is continued at a dose of at least 2 mg/kg bwt/day. The purpose of the 3 studies reported here was to 1) evaluate the evolution of potential effects of omeprazole paste (GastroGard), at a dose of 20 mg/kg bwt/day (5x the recommended dose) for 91 days in mature Thoroughbred horses; 2) evaluate the safety in young horses of omeprazole paste when dosed at 4 mg/kg bwt/day (1x), 12 mg/kg bwt/day (3x) or 20 mg/kg bwt/day (5x) for 91 days in Tennessee walking horse foals; and 3) evaluate the safety of omeprazole paste when dosed at 40 mg/kg bwt/day (10x) for 21 days in mature Thoroughbred horses. Within each study, horses were allocated randomly to the control or omeprazole paste treatment group. Clinical examinations, serum biochemistry and haematology were performed at regular intervals until necropsy at the end of the study. There were no treatment-related clinical signs in any treated horse and serum biochemistry and haematology were normal. In conclusion, omeprazole paste is safe for use in horses as demonstrated in studies with foals and mature horses.

Field trials evaluating ivermectin controlled-release capsules for weaner sheep and for breeding ewes.

OBJECTIVE: To confirm the efficacy of ivermectin released from a controlled-release capsule administered to young sheep and to breeding ewes under field conditions. DESIGN: Randomised field trials. PROCEDURE: In each of ten field trials 25 weaned lambs were treated with ivermectin controlled-release capsules and 25 remained untreated. Eight similar field trials were conducted using adult ewes. Efficacy against infections of gastrointestinal nematodes was assessed by faecal egg counts and faecal larval culture. Body weights were recorded and faecal soiling of the breech wool (dags) was assessed. RESULTS: Nematode faecal egg counts in the two groups were not different (P = 0.13) before treatment in the weaner trials or before treatment in the ewe trials (P = 0.49), but thereafter eggs in the untreated sheep persisted, whereas counts in sheep given capsules were negligible (P < or = 0.01). In the weaner trials, dag scores for the two groups were not different at the start of the trials (P = 0.18) but at the end, untreated sheep had significantly more dags (P = 0.04) than treated sheep. In the ewe trials, dag scores remained low in both groups. Weaners treated with the capsule gained 1.4 kg (95% CL: 0.7, 3.1) more weight over the 16 week trial period compared to untreated weaners (P = 0.01). Both groups of ewes lost weight as a result of parturition but the mean loss by week 16 was greater for untreated (3.7 kg) (95% CL: -5.1, -2.2) than for treated ewes (1.8 kg) (95% CL: -3.3, -0.4). The mean change in ewe body weight for the two groups was however not significant (P = 0.07). Differentiation of nematode larvae recovered from cultures of faeces from untreated animals indicated that the capsules were effective against the common parasites of sheep. CONCLUSION: The capsule was efficacious against gastrointestinal nematodes judging from faecal egg counts. It has the potential to significantly reduce contamination of pasture with nematode eggs. Treated weaners had less dags for 16 weeks and gained more weight than untreated weaners.

Efficacy of a pour-on formulation of eprinomectin (MK-397) against nematode parasites of cattle, with emphasis on inhibited early fourth-stage larvae of Ostertagia spp.

OBJECTIVE: To evaluate efficacy of topically applied eprinomectin against inhibited early fourth-stage larvae (IL4) of Ostertagia spp in calves. ANIMALS: 4 groups (n = 6 [replicates]) for dose titration; 2 groups (n = 8 calves [replicates]) for dose confirmation. PROCEDURE: 2 dose titration studies-0, 125, 250, and 500 micrograms of eprinomectin/kg of body weight-Louisiana and Georgia- and 2 dose confirmation studies of selected therapeutic dosage (500 micrograms/kg) in Scotland and France. Monitor calves were used to determine inhibition percentage of Ostertagia IL4. Test calves were ranked by weight in replicates of 4 (titration trials) or 2 (confirmation trials) animals each, and within replicates, were randomly allocated to treatment groups. Drug treatments were done on day 0, and animals were euthanatized by replicate, with holding time between treatment and euthanasia varying among trials from 14 to 27 days. RESULTS: Observations indicated high efficacy (> 99%) of 500 micrograms of eprinomectin/kg in removal of Ostertagia IL4. Ostertagia and Cooperia were only genera common across sites, with efficacy of aforementioned dosage against adult and larval stages of both genera consistently high (> 99%). Results of 1 or both titration studies (500 micrograms/kg) indicated > 99 to 100% efficacy against adult Haemonchus placei, Trichostrongylus axei, T colubriformis, Bunostomum phlebotomum, Dictyocaulus viviparus, and Oesophagostomum radiatum. Lower efficacy values were observed at minimal (125 micrograms/kg) dosage. In France, 500 micrograms/kg was 85% effective against Trichostrongylus spp adults; however, numbers of control calves infected with Trichostrongylus spp and degree of infection were low. Adverse reactions were not evident. CONCLUSION: Eprinomectin given topically (500 micrograms) was highly effective against Ostertagia IL4 and other common nematodes of cattle.

Field trials in New Zealand confirming the efficacy of eprinomectin applied topically to cattle.

The efficacy and acceptability of eprinomectin in a topical formulation against gastro-intestinal nematodes in cattle was assessed under field conditions. Seven similar commercial dairy farms in the North and South Islands of New Zealand were included in the studies, involving 247 Holstein-Friesian, Jersey or Jersey-cross cattle. Cattle were confirmed by positive faecal nematode egg counts to have natural infections of gastro-intestinal nematodes and were held in separate treatment groups. In each replicate, four animals received eprinomectin (500 microg/kg body weight) and one animal received vehicle solution, all applied topically at 1 ml/10 kg body weight. Faecal samples were collected before, and 14 days after treatment, for faecal trongylid egg counts. Animals treated with eprinomectin had significantly lower (p < 0.05) Day 14 faecal strongylid egg counts than the controls. There were no significant differences (p > 0.10) between treated and control groups for pretreatment strongylid egg counts. No formulation runoff or adverse reactions were observed. These studies showed eprinomectin to be effective against gastro-intestinal nematode infections and safe for use in dairy cattle under natural field conditions.

Efficacy of ivermectin delivered from a sustained-release bolus against inhibited early fourth-stage larvae of Ostertagia ostertagi and other nematodes in cattle.

The anthelmintic efficacy of ivermectin (IVM) delivered from a sustained-release (SR) bolus was evaluated against natural infections with gastrointestinal tract nematodes in 12 crossbred beef heifers in spring. The 12 calves were randomly allotted to 2 groups of 6 calves each. Group-1 calves were treated with an SR bolus designed to deliver 8 mg of ivermectin/d. Group-2 calves were nontreated controls. Cattle groups were kept in separate concrete-floored pens (grass hay nutrition) and slaughter was performed at 35 days after treatment. Fecal egg counts for group-1 calves remained zero after treatment, except for detection of less than 1 egg/g of feces in 1 calf at the time of slaughter; counts in nontreated calves increased. Mean and range of Ostertagia ostertagi inhibited larvae in nontreated calves were 27,093 and 10,622 to 56,368, respectively. Efficacy of the IVM SR bolus was 100% against O ostertagi developing fourth-stage larvae (L4) and inhibited early L4, Haemonchus placei adults, Cooperia punctata and C spatulata adult males, Cooperia spp adult females, Cooperia spp L4, Trichostrongylus colubriformis adults, Bunostomum phlebotomum adults, and Oesophagostomum radiatum adults. Efficacy for O ostertagi and T axei adults was 99.9%. Numbers of nontreated calves infected with C pectinata adult males and Oes radiatum L4 were too low to evaluate efficacy. Calves treated with the IVM bolus gained 10.2 kg, whereas nontreated calves lost 1.8 kg. Abomasal lesions were clearly greater in nontreated calves on the basis of index comparisons of abomasal weight and total live weight and gross pathologic features.

Efficacy of ivermectin and pyrantel pamoate combined in a chewable formulation against heartworm, hookworm, and ascarid infections in dogs.

Eight trials were conducted in dogs to document the efficacy of ivermectin (6 micrograms/kg of body weight) and pyrantel pamoate (5 mg of active pyrantel/kg) in a beef-based chewable formulation against Dirofilaria immitis, Ancylostoma caninum, Uncinaria stenocephala, Toxocara canis, and Toxascaris leonina. Three studies involved induced infection with D immitis, and 5 studies involved induced or natural infection with hookworms and ascarids. In 3 intestinal parasite trials, the efficacy of the combination chewable tablet was compared with each of its components. Results indicated that 1 component did not interfere with the activity of the other. In 1 heartworm and 2 intestinal parasite trials, the efficacy of pyrantel, ivermectin/pyrantel combination, or ivermectin with pyrantel dosage of 10 mg/kg was evaluated. The ivermectin/pyrantel combination was 100% effective in preventing development of D immitis larvae. Efficacy of the combined product against T canis, Toxascaris leonina, A caninum, and U stenocephala was 90.1, 99.2, 98.5, and 98.7%, respectively. In the intestinal parasite trials, each individual component was found not to interfere with the anthelmintic action of the other. Increasing the dosage of pyrantel to 10 mg/kg (2 x that in the combination) did not interfere with the efficacy of ivermectin against heartworm or increase the activity of pyrantel against intestinal parasites.

Efficacy of abamectin against natural infections of gastrointestinal nematodes and lungworm of cattle with special emphasis on inhibited, early fourth stage larvae of Ostertagia ostertagi.

The anthelmintic efficacy of abamectin (avermectin B1) was evaluated against gastrointestinal nematodes, including Ostertagia ostertagi inhibited larvae and lungworm, in yearling crossbred beef heifers during late spring. The calves were grazed on contaminated pasture for 10 weeks and then held under conditions free of nematode infection for 3 weeks prior to allotment and treatment on 5 June. Thirteen calves were randomly assigned to two groups of six by restricted randomization on body weights; the extra lightest calf was assigned to the non-treated control group. Group 1 calves were treated with abamectin at 200 micrograms kg-1 body weight by s.c. injection and Group 2 calves were not treated; all were killed at 14 days after treatment. Ostertagia ostertagi was present in all controls; arithmetic mean numbers of adults, developing fourth stage larvae (L4) and inhibited EL4 were 7683, 605 and 36,102, respectively. Other nematode genera present in controls in sufficient numbers for the experiment were Haemonchus placei adults, Trichostrongylus axei adults, Cooperia spp. adults, Oesophagostomum radiatum adults, Bunostomum phlebotomum adults, Dictyocaulus viviparus adults and E5 (immature adults). Abamectin was highly effective (consistently greater than 99% efficacy and P less than 0.05) in removing all nematodes present in treated calves as represented in non-treated controls, including the primary target of Ostertagia ostertagi inhibited EL4. The lowest efficacy was 93.8%, against D. viviparus E5.

Efficacy of ivermectin chewable tablets and two new ivermectin tablet formulations against Dirofilaria immitis larvae in dogs.

One hundred four heartworm-free Beagles less than 1 year old were studied to determine the efficacy of ivermectin chewable tablets and of 2 other ivermectin tablet formulations against heartworm larvae. At 30 days after SC inoculation of dogs with infective Dirofilaria immitis larvae, all ivermectin formulations were given orally at dosage of 6 micrograms/kg of body weight. The ivermectin chewable tablets also were given orally at dosage of 2 and 6 micrograms/kg at 30 and 45 days, respectively, after injection of larvae. Replicates of 6 or 8 dogs in each study were formed on the basis of gender and body weight and, within replicates, were randomly allocated to treatment groups. At 30 days after injection of larvae, the additional dogs (in replicates of 8) were assigned to the control group and to the group given ivermectin chewable tablets at dosage of 6 micrograms/kg. All dogs were housed individually. Necropsy was performed approximately 5 or 6 months after larvae were administered. In both trials, all control dogs had heartworms at necropsy (University of Illinois--geometric mean, 35.0; Florida--geometric mean, 26.1). In both trials, the ivermectin chewable tablet (6 micrograms/kg) and both tablet formulations (6 micrograms/kg) given at 30 days after larval injection, and the chewable formulation (6 micrograms/kg) given at 45 days after larval injection were 100% effective (P less than 0.01) in preventing development of induced infection with D immitis.(ABSTRACT TRUNCATED AT 250 WORDS)

Evaluation of the parasitological and production responses of a cow/calf operation to an anthelmintic program with ivermectin.

The efficacy of a treatment schedule using ivermectin, given subcutaneously at the rate of 200 micrograms kg-1, to control gastrointestinal parasitism and its effect on liveweight gains was assessed. Two herds with a total of 466 Hereford X Brangus cow/calf pairs were used. Each herd was on six pasture plots of comparable size, stocking rate, and quality and quantity of forage. Pasture groups were paired across the two herds. Pasture groups from one herd were randomly assigned to nonmedicated control and the other three to ivermectin treatment. Treatment assignments per pasture group were reversed in the other herd. The control group contained 118 cows and 112 calves and the medicated group 121 cows and 115 calves. Cows were treated in early July and the calves in late July or early August. Cattle from one herd were weighed on Days -28, 0 (day of cow treatment), 30 (day of calf treatment), 58, and 86, while the other herd was weighed on Days -29, 0 (day of cow treatment), 27 (day of calf treatment), 61, and 89. Day 0 was not the same calendar day for the two herds. Fecal samples for parasite egg counts were obtained from the rectum on weight days from five cows and six calves from each pasture; in most cases the same cattle were sampled each time. Calves treated with ivermectin gained (P less than 0.05) more weight than control calves between day of treatment for cows and the end of the trial.(ABSTRACT TRUNCATED AT 250 WORDS)

Efficacy and safety of clorsulon used concurrently with ivermectin for control of Fasciola hepatica in Florida beef cattle.

The safety and anthelmintic efficacy of clorsulon (7 mg/kg of body weight, orally) given concurrently with ivermectin (0.2 mg/kg, subcutaneously) for control of Fasciola hepatica were evaluated in 75 crossbred beef cattle. Twenty-three control animals were given only ivermectin. Fluke egg counts were significantly lower (P less than 0.0001) in clorsulon-treated animals by day 14 after treatment than before treatment (base line) and were significantly lower (P less than 0.005) after treatment in clorsulon-treated animals than in controls. There was no significant change in fluke egg counts of controls after treatment. The efficacy of clorsulon in reducing F hepatica egg counts was 99%. Clorsulon showed poor efficacy against paramphistomes. Adverse reactions were not observed.

Effect of ivermectin on performance of beef cattle on Georgia pastures.

A total of 469 cows and calves from 2 herds, each on 6 pastures, was used to evaluate the anthelmintic efficacy and animal-performance benefits of ivermectin given subcutaneously at a dosage of 200 micrograms/kg to nursing beef calves and their dams during a grazing season. Pastures were paired across the 2 herds. Three pasture groups from 1 herd were randomly assigned to either a nonmedicated control or to a medicated group. Treatment assignments were reversed in the other herd. The control groups comprised 110 cows and 108 calves, whereas 127 cows and 124 calves were treated with ivermectin (200 micrograms/kg). The cows were treated once, in late spring, and the calves were treated twice, once in late spring and again in midsummer. Cattle from one herd were weighed on days - 12, 21, 49, 77 (day of 2nd treatment for calves), and 105, and the other herd was weighed on days - 6, 23, 57, 86 (day of 2nd treatment for calves), and 113. Rectal fecal samples for nematode egg counts were obtained from approximately 25% of the cattle in each pasture on weighing days; usually, the same cattle were sampled each time. Calves treated with ivermectin gained (P less than 0.05) more weight than control calves up to the 2nd treatment date and up to the termination of the study. There was no significant difference between treated and control cows, with regard to weight gain over either interval. Treated calves had fewer positive fecal egg counts (P less than 0.01) and passed fewer eggs (P less than 0.05) after both treatments than did control calves. There were no differences in either number of eggs or number of negative cows between treatment groups. Adverse reactions attributable to treatment were not seen.

Protothecosis in a cat: first recorded case.

A 12-year-old Domestic Shorthair cat with a soft, fluctuant, subcutaneous mass, approximately 5 cm in diameter on the posterior aspect of the left tarsus was diagnosed as having protothecosis. Cultures, histopathology, and fluorescent antibody reagents were used to identify Prototheca wickerhamii as the etiologic agent. Protothecosis has not previously been recorded in cats.